NKTR - ネクタ―・セラピュ―ティクス (Nektar Therapeutics)

NKTRのニュース

   Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript | The Motley Fool  2020/05/08 07:31:06 The Motley Fool
NKTR earnings call for the period ending March 31, 2020.
   Cerus Corporation Announces Strategic Organizational Changes  2020/03/02 21:10:00 Benzinga Feeds
Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promoted to VP Development and Platelet/Plasma/Therapeutics Program Leader Cerus Corporation (NASDAQ: CERS ) today announced the promotion of three key leaders within the Company in anticipation of the Company's expected continued growth prospects, the anticipated approval and launch of multiple products over the next several years, as well as the need to realize greater operational effectiveness as the Company works to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302005230/en/ Cerus Corporation announced the promotion of chief commercial officer Vivek Jayaraman to chief operating officer. (Photo: Business Wire) "These promotions from within our senior leadership team are intended to create an organizational structure that is focused on the ownership of key deliverables, both commercially and across our development portfolio, and are expected to provide Cerus with the continued growth opportunities required to achieve its mission of making INTERCEPT Blood System the global standard of care in transfusion medicine," said William ‘Obi' Greenman, Cerus' president and chief executive officer. "Nina, Yasmin, and Vivek have led many of the activities that have been integral to Cerus' recent achievements and I am excited to welcome them into new leadership roles so that the organization can benefit from their considerable experience and expertise.
   Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for  2020/02/20 17:31:41 Zacks Investment Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know  2020/02/06 22:50:10 Zacks Investment Research
Nektar Therapeutics (NKTR) closed at $22.81 in the latest trading session, marking a -0.52% move from the prior day.
   Nektar Therapeutics Pullback May Be Short-Lived  2020/01/23 16:43:15 Schaeffers Investment Research
Nektar has struggled to gain momentum since its early August sell-off
   Nektar Therapeutics (NKTR) Q1 2020 Earnings Call Transcript | The Motley Fool  2020/05/08 07:31:06 The Motley Fool
NKTR earnings call for the period ending March 31, 2020.
   Cerus Corporation Announces Strategic Organizational Changes  2020/03/02 21:10:00 Benzinga Feeds
Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promoted to VP Development and Platelet/Plasma/Therapeutics Program Leader Cerus Corporation (NASDAQ: CERS ) today announced the promotion of three key leaders within the Company in anticipation of the Company's expected continued growth prospects, the anticipated approval and launch of multiple products over the next several years, as well as the need to realize greater operational effectiveness as the Company works to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302005230/en/ Cerus Corporation announced the promotion of chief commercial officer Vivek Jayaraman to chief operating officer. (Photo: Business Wire) "These promotions from within our senior leadership team are intended to create an organizational structure that is focused on the ownership of key deliverables, both commercially and across our development portfolio, and are expected to provide Cerus with the continued growth opportunities required to achieve its mission of making INTERCEPT Blood System the global standard of care in transfusion medicine," said William ‘Obi' Greenman, Cerus' president and chief executive officer. "Nina, Yasmin, and Vivek have led many of the activities that have been integral to Cerus' recent achievements and I am excited to welcome them into new leadership roles so that the organization can benefit from their considerable experience and expertise.
   Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for  2020/02/20 17:31:41 Zacks Investment Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know  2020/02/06 22:50:10 Zacks Investment Research
Nektar Therapeutics (NKTR) closed at $22.81 in the latest trading session, marking a -0.52% move from the prior day.
   Nektar Therapeutics Pullback May Be Short-Lived  2020/01/23 16:43:15 Schaeffers Investment Research
Nektar has struggled to gain momentum since its early August sell-off
   Cerus Corporation Announces Strategic Organizational Changes  2020/03/02 21:10:00 Benzinga Feeds
Vivek Jayaraman promoted to Chief Operating Officer Dr. Nina Mufti promoted to VP Development and Red Blood Cell Program Leader Dr. Yasmin Singh promoted to VP Development and Platelet/Plasma/Therapeutics Program Leader Cerus Corporation (NASDAQ: CERS ) today announced the promotion of three key leaders within the Company in anticipation of the Company's expected continued growth prospects, the anticipated approval and launch of multiple products over the next several years, as well as the need to realize greater operational effectiveness as the Company works to scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200302005230/en/ Cerus Corporation announced the promotion of chief commercial officer Vivek Jayaraman to chief operating officer. (Photo: Business Wire) "These promotions from within our senior leadership team are intended to create an organizational structure that is focused on the ownership of key deliverables, both commercially and across our development portfolio, and are expected to provide Cerus with the continued growth opportunities required to achieve its mission of making INTERCEPT Blood System the global standard of care in transfusion medicine," said William ‘Obi' Greenman, Cerus' president and chief executive officer. "Nina, Yasmin, and Vivek have led many of the activities that have been integral to Cerus' recent achievements and I am excited to welcome them into new leadership roles so that the organization can benefit from their considerable experience and expertise.
   Analysts Estimate Nektar Therapeutics (NKTR) to Report a Decline in Earnings: What to Look Out for  2020/02/20 17:31:41 Zacks Investment Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Nektar Therapeutics (NKTR) Stock Sinks As Market Gains: What You Should Know  2020/02/06 22:50:10 Zacks Investment Research
Nektar Therapeutics (NKTR) closed at $22.81 in the latest trading session, marking a -0.52% move from the prior day.
   Nektar Therapeutics Pullback May Be Short-Lived  2020/01/23 16:43:15 Schaeffers Investment Research
Nektar has struggled to gain momentum since its early August sell-off
   Why This Opioid Painkiller Is Killing Nektar Therapeutics Stock  2020/01/15 18:06:01 24/7 Wall street

calendar